AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16106594 — intervention group
Group type: EXPERIMENTAL
Intervention: Melagatran-ximelagatran (subcutaneous melagatran for 1-2 days followed by oral ximelagatran for 6-9 days)
Number of subjects: 14000
Study 16106594 — intervention group
Group type: EXPERIMENTAL
Intervention: Ximelagatran (oral for 7-12 days)
Number of subjects: 14000
Study 16106594 — intervention group
Group type: EXPERIMENTAL
Intervention: Melagatran-ximelagatran
Number of subjects: 14000
Study 16106594 — intervention group
Group type: COMPARATOR
Intervention: Ximelagatran
Number of subjects: 14000
Study 12021628 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 100 mg/day for 7 days
Number of subjects: 10
Study 12021628 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 10079409 — intervention group
Group type: EXPERIMENTAL
Intervention: Human preimplantation embryos cultured in vitro with endometrial stromal cells
Number of subjects: 0
Study 10079409 — intervention group
Group type: COMPARATOR
Intervention: Human preimplantation embryos cultured alone
Number of subjects: 0
Study 7497865 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolrestat 200 mg/day
Number of subjects: 57
Study 7497865 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 16296701 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5-10 mg/day)
Number of subjects: 40
Study 16296701 — intervention group
Group type: COMPARATOR
Intervention: Captopril (25-50 mg twice daily)
Number of subjects: 40
Study 16296701 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 40
Study 16296701 — intervention group
Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 40
Study 6212561 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide (5%)
Number of subjects: 0
Study 6212561 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide (10%)
Number of subjects: 0
Study 6212561 — intervention group
Group type: COMPARATOR
Intervention: Alcohol-free benzoyl peroxide gel
Number of subjects: 0
Study 31104962 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant therapy initiated within 61 days
Number of subjects: 16335
Study 31104962 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant therapy initiated after 61 days
Number of subjects: 16335
Study 28142285 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activities programme (N = 10)
Number of subjects: 19
Study 28142285 — intervention group
Group type: COMPARATOR
Intervention: Control condition (N = 9)
Number of subjects: 19
Study 25381429 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (RTX) at 375 mg/m² × 4
Number of subjects: 102
Study 25381429 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide (CYC) followed by Azathioprine (AZA) at 2 mg/kg/d after 3-6 months
Number of subjects: 102
Study 25381429 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (RTX)
Number of subjects: 102
Study 25381429 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide (CYC) followed by Azathioprine (AZA)
Number of subjects: 102
Study 25381429 — intervention group
Group type: EXPERIMENTAL
Intervention: Both RTX and CYC/AZA
Number of subjects: 102
Study 23883177 — intervention group
Group type: EXPERIMENTAL
Intervention: AFLY5 intervention
Number of subjects: 0
Study 21834404 — intervention group
Group type: EXPERIMENTAL
Intervention: Ease of retrieval of autobiographical events (participants retrieved 6 or 12 personal memories)
Number of subjects: 0
Study 21834404 — intervention group
Group type: COMPARATOR
Intervention: Reminder of the original number of recalled memories
Number of subjects: 0
Study 21834404 — intervention group
Group type: EXPERIMENTAL
Intervention: Discounting or augmenting ease of retrieval
Number of subjects: 0
Study 19244470 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone only (PO)
Number of subjects: 0
Study 19244470 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 0
Study 19244470 — intervention group
Group type: EXPERIMENTAL
Intervention: No acyclovir
Number of subjects: 0
Study 19244470 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17095924 — intervention group
Group type: EXPERIMENTAL
Intervention: PRE-POST group (supplement consumed immediately before and after RE)
Number of subjects: 0
Study 17095924 — intervention group
Group type: EXPERIMENTAL
Intervention: PRE-POST group
Number of subjects: 0
Study 17095924 — intervention group
Group type: COMPARATOR
Intervention: MOR-EVE group (supplement consumed in the morning and late evening)
Number of subjects: 0
Study 14999649 — intervention group
Group type: EXPERIMENTAL
Intervention: Profile-tailored CBT
Number of subjects: 131
Study 14999649 — intervention group
Group type: COMPARATOR
Intervention: Standard CBT
Number of subjects: 131
Study 14999649 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 131
Study 11159017 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchial macrophages from asthmatics with >5% airway eosinophils (AEo+)
Number of subjects: 20
Study 11159017 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchial macrophages from asthmatics
Number of subjects: 20
Study 9644630 — intervention group
Group type: EXPERIMENTAL
Intervention: Active lupus nephritis patients
Number of subjects: 0
Study 9644630 — intervention group
Group type: COMPARATOR
Intervention: Non-lupus nephropathies patients
Number of subjects: 0
Study 8190480 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketorolac (60 mg)
Number of subjects: 60
Study 8190480 — intervention group
Group type: COMPARATOR
Intervention: Oral acetaminophen (650 mg)
Number of subjects: 60
Study 8190480 — intervention group
Group type: COMPARATOR
Intervention: Oral ibuprofen (600 mg)
Number of subjects: 60
Study 3351819 — intervention group
Group type: EXPERIMENTAL
Intervention: One-minute alcohol wash followed by iodophor-impregnated adhesive film
Number of subjects: 79
Study 3351819 — intervention group
Group type: COMPARATOR
Intervention: Five-minute iodophor scrub followed by iodophor wash
Number of subjects: 79
Study 29931804 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) intervention with two MI sessions
Number of subjects: 99
Study 29931804 — intervention group
Group type: COMPARATOR
Intervention: Education control
Number of subjects: 99
Study 28222631 — intervention group
Group type: COMPARATOR
Intervention: 20 ml US‐TAP block (50 mg bupivacaine + 10 ml saline solution)
Number of subjects: 60
Study 28222631 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 ml US‐TAP block (50 mg bupivacaine + 20 ml saline solution)
Number of subjects: 60
Study 25877874 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased dose and frequency of albendazole and ivermectin
Number of subjects: 70
Study 25877874 — intervention group
Group type: COMPARATOR
Intervention: Standard dosage of ivermectin and albendazole
Number of subjects: 70
Study 23668478 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg/day
Number of subjects: 75
Study 23668478 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) 25 mg/day
Number of subjects: 75
Study 23668478 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 21499018 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based fall assessment
Number of subjects: 369
Study 21499018 — intervention group
Group type: COMPARATOR
Intervention: Hospital-based fall assessment
Number of subjects: 369
Study 19199847 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth intervention using Health Buddy(R) device for symptom management
Number of subjects: 0
Study 16724993 — intervention group
Group type: EXPERIMENTAL
Intervention: H(2)-receptor antagonist half-dose group
Number of subjects: 483
Study 16724993 — intervention group
Group type: EXPERIMENTAL
Intervention: H(2)-receptor antagonist full-dose group
Number of subjects: 483
Study 16724993 — intervention group
Group type: COMPARATOR
Intervention: Control group (no maintenance therapy)
Number of subjects: 483
Study 15289097 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine (3mg/kg/d for 12 weeks) plus prednisolone (reducing course starting at 40mg/d for 8 weeks)
Number of subjects: 40
Study 15289097 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone (reducing course starting at 40mg/d for 12 weeks)
Number of subjects: 40
Study 11422333 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ) at 800 mg/day
Number of subjects: 34
Study 11422333 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (GBP) at 2400 mg/day
Number of subjects: 34
Study 11422333 — intervention group
Group type: COMPARATOR
Intervention: Nondrug average
Number of subjects: 34
Study 8997461 — intervention group
Group type: EXPERIMENTAL
Intervention: mexiletine 600 mg/d
Number of subjects: 29
Study 8997461 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 29
Study 7688950 — intervention group
Group type: EXPERIMENTAL
Intervention: Panretinal photocoagulation for ischemic central vein occlusion
Number of subjects: 725
Study 7688950 — intervention group
Group type: EXPERIMENTAL
Intervention: Macular grid-pattern photocoagulation for macular edema
Number of subjects: 725
Study 7688950 — intervention group
Group type: EXPERIMENTAL
Intervention: Indeterminate group
Number of subjects: 725
Study 7688950 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfused group
Number of subjects: 725
Study 3281307 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline 0.5 mg (0.5 ml)
Number of subjects: 20
Study 3281307 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline 0.5 mg (0.5 ml)
Number of subjects: 20
Study 31205156 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% Patent Blue V (PB) for 10 minutes
Number of subjects: 15
Study 31205156 — intervention group
Group type: COMPARATOR
Intervention: 0.06% Trypan Blue (TB) for 4 minutes
Number of subjects: 15
Study 28263245 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzylpenicillin and Gentamicin
Number of subjects: 348
Study 28263245 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone
Number of subjects: 348
Study 28263245 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 348
Study 26572729 — intervention group
Group type: EXPERIMENTAL
Intervention: High Flow Nasal Cannula (HFNC) therapy
Number of subjects: 0
Study 26572729 — intervention group
Group type: COMPARATOR
Intervention: Standard subnasal oxygen therapy
Number of subjects: 0
Study 23178855 — intervention group
Group type: EXPERIMENTAL
Intervention: Pascal TargETEd Retinal photocoagulation (TRP)
Number of subjects: 24
Study 23178855 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally-traumatic panretinal photocoagulation (MT-PRP)
Number of subjects: 24
Study 23178855 — intervention group
Group type: COMPARATOR
Intervention: Standard-intensity PRP (SI-PRP)
Number of subjects: 24
Study 23178855 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (TRP, MT-PRP, SI-PRP)
Number of subjects: 24
Study 22045289 — intervention group
Group type: EXPERIMENTAL
Intervention: IV tPA and continuous TCD monitoring
Number of subjects: 126
Study 22045289 — intervention group
Group type: COMPARATOR
Intervention: Placebo monitoring
Number of subjects: 126
Study 19117153 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam 8 mg administered PO
Number of subjects: 40
Study 19117153 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam 8 mg administered IM
Number of subjects: 40
Study 19117153 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam 8 mg administered IV
Number of subjects: 40
Study 19117153 — intervention group
Group type: COMPARATOR
Intervention: Control group (no analgesia)
Number of subjects: 40
Study 17006858 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg of bromazepam (B3)
Number of subjects: 14
Study 17006858 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg of bromazepam (B6)
Number of subjects: 14
Study 17006858 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 14
Study 15029039 — intervention group
Group type: EXPERIMENTAL
Intervention: C974P (0.25% fluid carbomer gel)
Number of subjects: 169
Study 15029039 — intervention group
Group type: COMPARATOR
Intervention: C940 (conventional carbomer gel)
Number of subjects: 169
Study 10875830 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 8897086 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenolol (100 mg)
Number of subjects: 24
Study 8897086 — intervention group
Group type: COMPARATOR
Intervention: Tenormin (reference product)
Number of subjects: 24
Study 1509999 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous flecainide (2 mg/kg, maximum dose 150 mg)
Number of subjects: 102
Study 1509999 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 6881917 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplements
Number of subjects: 203
Study 6881917 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203
Study 6881917 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal folate levels
Number of subjects: 203
Study 6881917 — intervention group
Group type: EXPERIMENTAL
Intervention: Folate supplementation
Number of subjects: 203
Study 31800425 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous TXA (1.0 g before tourniquet inflation and again 3 hours later)
Number of subjects: 76
Study 31800425 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical TXA (3.0 g administered 5 minutes before final tourniquet release)
Number of subjects: 76
Study 29032288 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Skills Training Program for adults with WS (SSTP‐WS)
Number of subjects: 30
Study 26293215 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone text message reminders for 12 months
Number of subjects: 562
Study 26293215 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone text message reminders
Number of subjects: 562
Study 23892922 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated G-CSF
Number of subjects: 249
Study 23892922 — intervention group
Group type: EXPERIMENTAL
Intervention: Unpegylated G-CSF
Number of subjects: 249
Study 23892922 — intervention group
Group type: COMPARATOR
Intervention: Three G-CSF schedules (pegylated and unpegylated)
Number of subjects: 249
Study 21350110 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren (150 mg force titrated to 300 mg daily after 3 months) plus losartan (100 mg)
Number of subjects: 599
Study 21350110 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus losartan (100 mg)
Number of subjects: 599
Study 19657288 — intervention group
Group type: EXPERIMENTAL
Intervention: Underwater treadmill (UTM) training
Number of subjects: 57
Study 19657288 — intervention group
Group type: EXPERIMENTAL
Intervention: Land treadmill (LTM) training
Number of subjects: 57
Study 17275781 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behaviour therapy (CBT)
Number of subjects: 20
Study 17275781 — intervention group
Group type: COMPARATOR
Intervention: Wait list (NL)
Number of subjects: 20
Study 15165919 — intervention group
Group type: EXPERIMENTAL
Intervention: Black tea
Number of subjects: 10
Study 15165919 — intervention group
Group type: COMPARATOR
Intervention: Caffeine
Number of subjects: 10
Study 11847727 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist band plus standard care plus next‐day phone call
Number of subjects: 61
Study 11847727 — intervention group
Group type: COMPARATOR
Intervention: Standard care plus next‐day phone call
Number of subjects: 61
Study 11847727 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist band
Number of subjects: 61
Study 11847727 — intervention group
Group type: EXPERIMENTAL
Intervention: Next‐day phone call
Number of subjects: 61
Study 11847727 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients aged 65 years and older
Number of subjects: 61
Study 9596323 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (8 weeks, twice daily) in patients with reduced ejection fraction (<40%)
Number of subjects: 67
Study 9596323 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care) in patients with normal ventricular function (>50%)
Number of subjects: 67
Study 9596323 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care) in patients with reduced ventricular function (<40%)
Number of subjects: 67
Study 9596323 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (8 weeks, twice daily) in patients with normal ventricular function (>50%)
Number of subjects: 67
Study 7851267 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary albumin/creatinine ratio
Number of subjects: 89
Study 3378382 — intervention group
Group type: EXPERIMENTAL
Intervention: m-chlorophenylpiperazine (m-CPP), 0.5 mg/kg
Number of subjects: 52
Study 3378382 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 3378382 — intervention group
Group type: COMPARATOR
Intervention: L-tryptophan, 100 mg/kg (IV)
Number of subjects: 52
Study 3378382 — intervention group
Group type: EXPERIMENTAL
Intervention: m-chlorophenylpiperazine (m-CPP)
Number of subjects: 52
Study 31691621 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimicifuga racemosa (160 mg dry extract with 4 mg of triterpene glycosides)
Number of subjects: 62
Study 31691621 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 31691621 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimicifuga racemosa
Number of subjects: 62
Study 31116919 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal high-flow therapy
Number of subjects: 754
Study 31116919 — intervention group
Group type: COMPARATOR
Intervention: CPAP
Number of subjects: 754
Study 31116919 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal high-flow therapy (per-protocol analysis)
Number of subjects: 754
Study 31116919 — intervention group
Group type: COMPARATOR
Intervention: CPAP (per-protocol analysis)
Number of subjects: 754
Study 31116919 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal high-flow therapy and CPAP
Number of subjects: 754
Study 28818450 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapist-led exercise intervention
Number of subjects: 128
Study 24744399 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiving experience prior to hospice enrollment
Number of subjects: 0
Study 23831174 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology-based multi-component psychosocial intervention delivered in-home via videophone technology over 5 months.
Number of subjects: 110
Study 23831174 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology-based multi-component psychosocial intervention
Number of subjects: 110
Study 21272743 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stenting (n = 100)
Number of subjects: 201
Study 21272743 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG) (n = 101)
Number of subjects: 201
Study 19198022 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG solution and simethicone (Group 2)
Number of subjects: 64
Study 19198022 — intervention group
Group type: COMPARATOR
Intervention: PEG solution (Group 1)
Number of subjects: 64
Study 16325899 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker feedback group (BF)
Number of subjects: 617
Study 16325899 — intervention group
Group type: COMPARATOR
Intervention: Follow-up smoking status group (FS)
Number of subjects: 617
Study 16325899 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker feedback group (BF) for non-cancer subjects
Number of subjects: 617
Study 16325899 — intervention group
Group type: COMPARATOR
Intervention: Follow-up smoking status group (FS) for non-cancer subjects
Number of subjects: 617
Study 16325899 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker feedback group (BF) for females
Number of subjects: 617
Study 16325899 — intervention group
Group type: COMPARATOR
Intervention: Follow-up smoking status group (FS) for females
Number of subjects: 617
Study 16325899 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker feedback group (BF) with risky genotype
Number of subjects: 617
Study 14719211 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of 2 drugs (rifampicin + cotrimoxazole or doxycycline)
Number of subjects: 90
Study 14719211 — intervention group
Group type: COMPARATOR
Intervention: Combination of 3 drugs (streptomycin + rifampicin + doxycycline)
Number of subjects: 90
Study 14719211 — intervention group
Group type: COMPARATOR
Intervention: Treatment duration of 5 months or less
Number of subjects: 90
Study 14719211 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment duration of more than 5 months
Number of subjects: 90
Study 10758521 — intervention group
Group type: EXPERIMENTAL
Intervention: Bed Positioning Program (BPP) for 8 weeks
Number of subjects: 16
Study 10758521 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control) for 8 weeks
Number of subjects: 16
Study 8821516 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglitol 100 mg, 3 times daily for 7 days
Number of subjects: 0
Study 8821516 — intervention group
Group type: COMPARATOR
Intervention: Placebo, 3 times daily for 7 days
Number of subjects: 0
Study 8821516 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglitol 100 mg with 25 mg warfarin on Day 4
Number of subjects: 0
Study 8821516 — intervention group
Group type: COMPARATOR
Intervention: Placebo with 25 mg warfarin on Day 4
Number of subjects: 0
Study 1453585 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous cyclic peritoneal dialysis (CCPD)
Number of subjects: 16
Study 1453585 — intervention group
Group type: COMPARATOR
Intervention: Continuous ambulatory peritoneal dialysis (CAPD)
Number of subjects: 16
Study 3881309 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (two 10-mg capsules t.i.d.)
Number of subjects: 8
Study 3881309 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical capsules)
Number of subjects: 8
Study 3881309 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 8
Study 31288925 — intervention group
Group type: EXPERIMENTAL
Intervention: Local Anesthesia (LA)
Number of subjects: 18
Study 31288925 — intervention group
Group type: COMPARATOR
Intervention: All Others (AO)
Number of subjects: 18
Study 29678170 — intervention group
Group type: EXPERIMENTAL
Intervention: Suture repair group with dynamic augmentation and microfracture of the femoral notch
Number of subjects: 48
Study 29678170 — intervention group
Group type: COMPARATOR
Intervention: ACL reconstruction group with autologous semitendinosis graft and all-inside technique
Number of subjects: 48